• Publications
  • Influence
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
TLDR
Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence, which may improve the accuracy of tumor grading and thus its prognostic value. Expand
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
TLDR
The association between pathological complete response and long-term outcomes was strongest in patients with triple-negative breast cancer, and the prognostic value is greatest in aggressive tumour subtypes. Expand
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
TLDR
Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors. Expand
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
TLDR
This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases. Expand
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
TLDR
The use of genomic grade can identify two clinically distinct ER-positive molecular subtypes in a simple and highly reproducible manner across multiple data sets and emphasizes the important role of proliferation-related genes in predicting prognosis in ER- positive BC. Expand
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
TLDR
Letrozole after tamoxifen is well-tolerated and improves both disease- free and distant disease-free survival but not overall survival, except in node-positive patients. Expand
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
TLDR
Although proliferation is the strongest parameter predicting clinical outcome in the ER+/HER2− subtype and the common denominator of most prognostic gene signatures, immune response and tumor invasion seem to be the main molecular processes associated with prognosis in theER−/her2− and HER2+ subgroups, respectively. Expand
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to
TLDR
In node-positive, ER-negative/HER2-negative BC, increasing lymphocytic infiltration was associated with excellent prognosis and the data also support the evaluation of immunotherapeutic approaches in selected BC subtypes. Expand
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
TLDR
As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival. Expand
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of
TLDR
The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care. Expand
...
1
2
3
4
5
...